Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: Most Read Cardiology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of March ...

March 31, 2022

The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held April 3-5 at the Bella Center in Copenhagen, Denmark and online. Explore the scientific program.

News | ESC

EHRA 2022: Cutting Edge Science in Heart Rhythm Disorders

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

March 31, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022

Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR).

News | Embolization devices

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

March 31, 2022

Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal+, the next generation of the company’s PerQseal device.

News | Structural Heart

Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+

March 31, 2022 – Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel ...

March 31, 2022

One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke.

News | Heart Failure

The Silent, Undetected Cause of Early Heart Disease

March 31, 2022 – One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an ...

March 31, 2022

University Hospitals Cleveland Medical Center

News | Population Health

Study Shows Link Between Socioeconomic Deprivation and Premature Cardiovascular Mortality

March 31, 2022 – People living in socially-deprived areas of the United States are more likely to die prematurely from ...

March 31, 2022

Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that, for the first time, distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.

News | Sudden Cardiac Arrest

Cedars-Sinai Researchers Are the First to Distinguish Between Treatable and Untreatable Sudden Cardiac Arrest

March 30, 2022 — Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that ...

March 30, 2022

Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) approved the use of a second COVID-19 booster shot for adults over age 50 and certain immunocompromised individuals, including heart transplant patients.

News | Coronavirus (COVID-19)

Second Booster Approved as Option for Additional Protection Against COVID-19

March 29, 2022 — Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention ...

March 29, 2022

Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has successfully completed the requirements for certification of its quality management system (QMS) under the new Medical Device Regulation (MDR) (EU 2017/745 ) now in force in the European Union (EU).

News | Heart Failure

Impulse Dynamics' Quality Management System Receives Certification Under European Union Medical Device Regulation

March 29, 2022 – Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has ...

March 29, 2022

Eko, a digital health company advancing heart and lung disease detection, has announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease.

News | Heart Failure

Eko Launches Screening Solution to Help Catch Heart Disease Early

March 29, 2022 – Eko, a digital health company advancing heart and lung disease detection, has announced the launch of ...

March 29, 2022

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, has received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

News | Embolization devices

Artio Medical Receives FDA Clearance for Solus Gold Embolization Device

March 29, 2022 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral ...

March 29, 2022

HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, announced another major milestone in the ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS), a first-of-its-kind patented, adjustable system which focuses on treating devastating left heart diseases, congestive heart failure, and structural pulmonary hypertension.

News | Heart Failure

HeartPoint Global's Implant System Proves Safety and Efficacy

March 28, 2022 — HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally ...

March 28, 2022

Aeson total artificial heart showing Open view with pumps and electronics (blue), blood chambers (maroon) and conduits (top, white). Image courtesy of Carmat.

News | Artificial Heart

Carmat Announces the Restart of Production

March 28, 2022 — Carmat, the designer and developer of the world’s most advanced total artificial heart, aiming to ...

March 28, 2022

In the first study to examine differences by sex and race in outcomes following the seven most common procedures for heart problems, researchers found that women are less likely to undergo these procedures—and even when women do receive these procedures, they are more likely than men to die while in the hospital, according to data that will be presented at the American College of Cardiology’s 71st Annual Scientific Session.

News | Womens Cardiovascular Health

Women Less Likely to Receive Life-saving Heart Procedures

March 25, 2022 – In the first study to examine differences by sex and race in outcomes following the seven most common ...

March 25, 2022